VIP
A vasoactive intestinal peptide associated with neuroimmune and inflammatory signaling discussions.
Also referenced as: Vasoactive Intestinal Peptide
This compound has a genuine development or study trail, but it is not an approved routine drug.
This profile is grouped by its dominant research and market lane, not by vendor shelf placement.
Vasoactive Intestinal Peptide
No FDA label signal · 52 trials · 1000 PubMed results
What VIP is
VIP stands for vasoactive intestinal peptide, a signaling peptide that shows up in immune, inflammatory, and neuroregulatory discussions.
Why it matters
It broadens the immune category beyond simple host-defense framing and reflects the fact that some peptide interest is really about signaling networks rather than bodybuilding or cosmetic use.
Regulatory context
VIP is not an FDA-approved general wellness peptide in the United States. It is best treated as an investigational or research-context entry.
Practical reading note
The more complex the signaling story around a peptide, the more important it is to avoid collapsing it into simple consumer promises.